Open Letter to the JCVI

9 December 2021


  • Professor Lim, Chairman, JCVI COVID-19 subcommittee
  • Dr June Raine, Chief Executive, MHRARt
  • Hon Sajid Javid, Secretary of State for Health and Social Care
  • Professor Chris Whitty, Chief Medical Officer for England
  • Sir Patrick Vallance, Government Chief Scientific Adviser
  • Dr Jenny Harries, Chief Executive, UKHSA

Dear Professor Lim, Dr Raine, Mr Javid, Professor Whitty, Sir Patrick Vallance & Dr Harries,


  • (I) latest government guidance re myocarditis
  • (II) decision to offer a second dose of Pfizer to 12-15s
  • (III) reckless disregard for the benefits of natural immunity in children

As a group of senior scientists and clinicians, we wrote to you only two weeks ago regarding your decision to offer a second dose of the Pfizer COVID-19 vaccine to 16-17-year-olds despite lack of detailed safety data. We still await a reply, but are compelled to write again after this week’s UKHSA publication of guidance on myocarditis, coinciding with your latest unexpected advice to widen the age range for the second dose to include 12-15 year-olds. We also still awaiting a reply as to why the JCVI continue to recommend vaccination for those children who already have naturally-acquired immunity and for whom there is no possibility of any benefit from the COVID-19 vaccines.

I. Myocarditis guidelines

The following statements (in italics) from the UKHSA document require urgent clarification regarding our points (in red).

  • “myocarditis and pericarditis following vaccination is usually mild or stable and most patients typically recover fully without medical treatment”

This unsubstantiated assertion is not compatible with the statement made in the bullet point below. Unless these children had cardiac MRI scans and follow-up, it is impossible to state that they ‘typically recover fully’

  • “myocarditis – significant left ventricular (LV) fibrosis has been described in a high percentage of children admitted to hospital, with a small percentage of these having non-sustained ventricular tachycardia (VT)”

According to the authors, these children were not clinically distinguishable from children in other case series, also with an apparently ‘mild’ clinical course. The concerning findings on MRI were only discovered because the authors thoroughly investigated all children with serious VAEs.

  • no follow-up data is available yet on hospitalised patients”

This point undermines the claim made in the first bullet point.

  • “the long-term consequences of this condition secondary to vaccination are yet unknown, so any screening recommendations need to be balanced against the frequency and severity of the disease with the aim to prevent complications, in particular of myocarditis (arrhythmias, long term myocardial damage or heart failure)”

As Pfizer have admitted, the children’s trials are too small to look for myocarditis, but long term studies are in progress due to report in 2025 Recommendations in paediatric patients: Why was there no consultation with the RCPCH?

  • Where appropriate, the patient should be seen face to face and this assessment should include their vital signs.”

When would it be ‘inappropriate’ to see face to face and check vital signs, in a child with any of the concerning symptoms listed?

  • If patients have mild symptoms, they do not require referral to secondary care at this point.”

How would you expect a GP to determine whether myocarditis was ‘mild’ in the absence of an ECG and a Troponin level? How does such an approach match up with rigorous post-marketing surveillance of a vaccine still under emergency use authorisation?

(II) Decision to offer a second dose of Pfizer to 12-15s

There has been no new follow-up data disclosed since the JCVI decision to offer only one dose to 12-15s regarding the outcome for children with vaccine-induced myocarditis. The suggestion that the MHRA has seen no new adverse event reports of myocarditis, is perhaps not surprising given that the UK has not proceeded to a second dose known to be associated with a greatly increased risk. How does the JCVI look at the concerns outlined in the government’s own myocarditis guidance and reconcile them with their duty of care to First do no Harm?

A systematic study from Hong Kong linking all vaccinations to health records has revealed myocarditis occurring 1 in 2,680 in young males after their second dose of Pfizer, and they have now dropped the second dose from their schedule. The latest FDA data similarly report 1 in 5000 for males age 16-17. How is it ethical to recommend a second dose to this cohort knowing the risks to the individual will far outweigh any benefits?

How will effective pharmacovigilance and real-time data be obtained on every child admitted with a diagnosis of myocarditis by vaccine status? How many child fatalities have you factored in as acceptable collateral damage resulting from your decision to recommend the second dose of this vaccine for a condition which poses no significant threat to this age group? The answer surely must be zero.

III. Naturally acquired immunity in children

Perhaps most pressing of all, why does the JCVI continue to disregard the obvious benefits of naturally acquired immunity? This has now been conclusively shown in adults to be much longer lasting and robust than that following vaccination . It is already known that children have good crossover immunity from previous coronaviruses, with excellent T-cell function. And it is widely recognised that their strong innate immune systems are the reason for Covid-19 being extremely mild in children. It is estimated that in England, 5.47 million 5-14-year-olds have already had SARS-CoV-2 infection (which represents 79% of the population of this age group). An international meta-analysis of re-infections post natural infection reported only 577 cases of reinfection from 22 countries over a 15-month period, including only 10 deaths, with not a single death in younger adults let alone in children. Numerous other publications have affirmed that naturally acquired immunity is robust, comprehensive and long-lasting.

Therefore, for the 80% of children who are already immune, there can be no benefit from vaccination and only the potential for serious or even life-threatening harm. For the 20% not yet infected, there are still unanswered questions about the potential for vaccination to interfere with the ability to mount a broad robust and long-lasting immunity and we risk committing these children to the theatre of ever more frequent boosters, each with its own risk of injury, which now seems to be the future for adults. Indeed, this becomes even more important with the new omicron variant. There is no point in vaccinating children with a vaccine which will cause immune imprinting to the Wuhan variant and will impede their ability to make antibodies to the new variants as they present.

We contend that any practitioner who chooses to vaccinate a child in the knowledge that they have recovered from SARS-CoV-2 infection, is in breach of their professional duty of care to put their patient’s best interest first. In addition. failure of the practitioner to disclose the full contents of the UKHSA Myocarditis guidance to the patient and parent would constitute a failure to obtain fully informed consent. See GMC Good Medical Practice Guidelines.

Yours sincerely,

  • Dr Rosamond Jones, MD, FRCPCH, retired consultant paediatrician
  • Professor Anthony J Brookes, Department of Genetics & Genome Biology, University of Leicester Professor David Livermore, BSc, PhD, Professor of Medical Microbiology, University of East Anglia
  • Professor Angus Dalgleish, MD, FRCP, FRACP, FRCPath, FMed Sci, Professor of Oncology, St Georges Hospital, London
  • Dr Theresa Lawrie, MBBCh, PhD, Director, Evidence-Based Medicine Consultancy Ltd, Bath
  • Dr Clare Craig, BMBCh, FRCPath, Pathologist
  • John Collis, RN, Retired specialist nurse practitioner
  • Professor Keith Willison, PhD, Professor of Chemical Biology, Imperial, London
  • Professor Richard Ennos, MA, PhD. Honorary Professorial Fellow, University of Edinburgh Professor John Fairclough FRCS FFSEM retired Honorary Consultant Surgeon
  • Lord Moonie, MBChB, MRCPsych, MFCM, MSc, House of Lords, former parliamentary under- secretary of state 2001-2003, former consultant in Public Health Medicine
  • Dr Roland Salmon, MBBS, MRCGP, FFPH, former Director, Communicable Disease Surveillance Centre, Wales
  • Dr John Flack, BPharm, PhD. Retired Director of Safety Evaluation, Beecham Pharmaceuticals 1980-1989 and Senior Vice-president for Drug Discovery 1990-92 SmithKline Beecham
  • Dr Alan Mordue, MBChB, FFPH. Retired Consultant in Public Health Medicine & Epidemiology
  • Dr Geoffrey Maidment, MD, FRCP, retired consultant physician
  • Dr Helen Westwood MBChB MRCGP DCH DRCOG, General Practitioner
  • Mr James Royle, MBChB, FRCS, MMedEd, Colorectal surgeon Dr Elizabeth Evans MA(Cantab), MBBS, DRCOG, Retired Doctor Dr Emma Brierly, MRCGP, General Practitioner
  • Katherine MacGilchrist, BSc (Hons), MSc, CEO/Systematic Review Director, Epidemica Ltd.
  • Dr Alan Black, MBBS, MSc, DipPharmMed, retired pharmaceutical physician
  • Mr Anthony Hinton, MBChB, FRCS, Consultant ENT surgeon, London
  • Dr Greta Mushet, MBChB, MRCPsych, retired Consultant Psychiatrist in Psychotherapy
  • Dr Kulvinder Singh Manik MBChB, MRCGP, MA(Cantab), LLM, Gray’s Inn
  • Dr Rohaan Seth, Bsc (hons), MBChB (hons), MRCGP, Retired General Practitioner
  • Mr Ian F Comaish, MA, BM BCh, FRCOphth, FRANZCO, Consultant ophthalmologist
  • Dr Sarah Myhill, MBBS, Dip NM, Retired GP, Independent Naturopathic Physician
  • Dr Christopher Exley, PhD, FRSB, Retired professor in Bioinorganic Chemistry
  • Dr David Critchley, BSc, PhD, 32 years in pharmaceutical R&D as a clinical research scientist. Dr Gerry Quinn, PhD. Postdoctoral researcher in microbiology and immunology
  • Dr Jonathan Engler, MBChB, LlB (hons), DipPharmMed
  • Dr Mark Bell, MBChB, MRCP(UK), FRCEM, Consultant in Emergency Medicine
  • Dr Zac Cox, BDS, LCPH, Holistic Dentist, Homeopath
  • Dr Elizabeth Burton, MBChB, retired general practitioner
  • Margaret Moss, MA (Cantab), CBiol, MRSB, Director, The Nutrition and Allergy Clinic, Cheshire
  • Julia Annakin, RN,
  • Dr Noel Thomas, MA, MBChB, DCH, DObsRCOG, DTM&H, MFHom, retired doctor
  • Immunisation Nurse Specialist
  • Dr Fiona Martindale, MbChB, MRCGP, GP in out of hours
  • Dr Branko Latinkic, BSc, PhD, Molecular biologist
  • Dr Jason Lester, MRCP, FRCR, Consultant Clinical Oncologist.
  • Dr Sam White, MBChB MRCGP, General Practitioner, Functional medicine practitioner
  • Dr Holly Young, BSc, MBChB, MRCP, Consultant Palliative Care Medicine
  • Dr David Bramble, MB ChB, MRCPsych, MD, Retired Consultant Child & Adolescent Learning Disability
  • Dr. Scott Mitchell, MBChB, MRCS, Associate Specialist, Emergency Medicine
  • Dr Peter Chan, BM, MRCS, MRCGP, General Practitioner, Functional medicine practitioner
  • Dr Stefanie Williams, Dermatologist
  • Dr Andrew Isaac, MB BCh, Physician, retired
  • Dr Christina Peers, MBBS, DRCOG, DFSRH, FFSRH, Menopause specialist
  • Dr Michael D Bell, MBChB, MRCGP, retired General Practitioner
  • Dr Livia Tossici-Bolt, PhD, NHS Clinical Scientist
  • Dr Carmen Wheatley, D Phil, Orthomolecular Oncology
  • Dr Ruth Wilde, MB BCh, MRCEM, AFMCP, Integrative & Functional Medicine Doctor
  • Dr David Morris, MBChB, MRCP(UK), General Practitioner
  • Dr Jayne LM Donegan, MBBS, DRCOG, DCH, DFFP, MRCGP, HMA, Integrative Medicine practitioner
  • Dr Franziska Meuschel, MD, ND, PhD, LFHom, BSEM, Nutritional, Environmental and Integrated Medicine
  • Dr Stefanie Williams, Dermatologist
  • Dr Andrew Isaac, MB BCh, Physician, retired
Please follow and like us:
Visit Us